Investigational biologic cleared skin better, faster and for longer than ustekinumab in Phase II psoriasis study

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066*, over ustekinumab.